Yahoo Finance Apontis Pharma Reports Full Year 2023 Earnings
Apontis Pharma (ETR:APPH) Full Year 2023 Results
Key Financial Results
Revenue: €38.7m (down 31% from FY 2022).
Net loss: €11.3m (down from €2.69m profit in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Apontis Pharma Earnings Insights
Looking ahead, revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany.
Performance of the German Pharmaceuticals industry.
The company's shares are down 2.2% from a week ago.
Risk Analysis
Before we wrap up, we've discovered 1 warning sign for Apontis Pharma that you should be aware of.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
